Lung function in preterm infants at 3 months corrected age after neonatal LC-PUFA supplementation
- PMID: 37975489
- DOI: 10.1002/ppul.26760
Lung function in preterm infants at 3 months corrected age after neonatal LC-PUFA supplementation
Abstract
Objective: To test the hypothesis that long-chain polyunsaturated fatty acid (LC-PUFA) supplementation improves lung function at 3 months corrected age (CA) compared with standard treatment in very preterm infants. We also aimed to investigate the association between bronchopulmonary dysplasia (BPD), longitudinal growth, and lung function at 3 months CA.
Methods: A secondary analysis from the ImNuT trial, in which 121 infants with gestational age <29 weeks were randomized to a daily supplement with arachidonic acid (ARA) and docosahexaenoic acid (DHA) (ARA:DHA group) or MCT-oil (control group) from birth up to 36 weeks postmenstrual age (PMA). Lung function was assessed at 3 months CA by tidal flow volume loops and the outcomes were the ratio of time to peak tidal expiratory flow to expiratory time (tPTEF /tE ) and tidal volume (VT ) per body weight (mL/kg).
Results: Thirty-nine infants in the ARA:DHA group versus 51 in the control group had a successful lung function test. There was no mean difference (MD) in tPTEF /tE ratio (MD: 0.01, 95% confidence interval [CI]: -0.04 to 0.05; p = .77) or VT (MD: 0.09 mL/kg, 95% CI: -0.79 to 0.62; p = .81) between the study groups. The multivariable regression model showed that BPD was associated with tPTEF /tE ratio ≤ 0.25 (p = .03) and that an increase in z score for length after 36 weeks PMA correlated positively with VT (mL/kg) (p = .03).
Conclusion: Neonatal LC-PUFA supplementation did not improve lung function at 3 months CA in very preterm infants. BPD was independently associated with reduced lung function, while improved linear growth correlated with higher tidal volumes.
Keywords: arachidonic acid; bronchopulmonary dysplasia; docosahexaenoic acid; pulmonary function; tidal breathing parameters.
© 2023 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.
References
REFERENCES
-
- Bell EF, Hintz SR, Hansen NI, et al. Mortality, in-hospital morbidity, care practices, and 2-year outcomes for extremely preterm infants in the US, 2013-2018. JAMA. 2022;327(3):248-263.
-
- Um-Bergström P, Hallberg J, Thunqvist P, et al. Lung function development after preterm birth in relation to severity of bronchopulmonary dysplasia. BMC Pulm Med. 2017;17(1):97.
-
- Bose CL, Dammann CEL, Laughon MM. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal Ed. 2008;93(6):F455-F461.
-
- Leuti A, Maccarrone M, Chiurchiù V. Proresolving lipid mediators: endogenous modulators of oxidative stress. Oxid Med Cell Longevity. 2019;2019:1-12.
-
- Collins CT, Makrides M, McPhee AJ, et al. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants. N Engl J Med. 2017;376(13):1245-1255.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
